Opalski Syndrome Treated with Intravenous Recombinant Tissue Type Plasminogen Activator-Case Report and Review of Literature

J Stroke Cerebrovasc Dis. 2020 Aug;29(8):104806. doi: 10.1016/j.jstrokecerebrovasdis.2020.104806. Epub 2020 May 17.

Abstract

A 65-year-old man with a history of Wallenberg syndrome caused by vertebral artery dissection at 62 years old was admitted to our hospital with nausea, vertigo, right facial dysesthesia, right hemiplegia, crossed sensory disturbance (sensory loss and numbness in the right face and left body below the neck), and right limb ataxia. Magnetic resonance imaging (MRI) performed 80 minutes after onset revealed no acute ischemic stroke lesions, but magnetic resonance angiography (MRA) demonstrated complete occlusion of the right vertebral artery. Based on these neurological and MRA findings, atypical lateral medullary infarction was suggested, and intravenous tissue plasminogen activator (IV-tPA) was started 178 minutes after onset. Right hemiplegia improved immediately after IV-tPA administration. MRI performed on hospital day 2 showed an acute ischemic lesion on the right side of the medulla oblongata, resulting in a diagnosis of Opalski syndrome. Opalski syndrome is a rare subtype of Wallenberg syndrome accompanied by hemiplegia of the side ipsilateral to the lesion, and expansion of the stroke lesion to the corticospinal tract below the pyramidal decussation is considered to cause ipsilateral hemiplegia. Based on this case and previous reports, Opalski syndrome should be considered when limb ataxia and crossed sensory deficit are observed among patients with hyperacute-onset hemiplegia, and IV t-PA therapy should be considered even in the absence of neurological findings such as dysphagia, dysarthria, and Horner's signs and radiological evidence of acute ischemic stroke.

Keywords: Opalski syndrome; Wallenberg syndrome; cerebral infarction; recombinant tissue type plasminogen activator; vertebral artery; vertebral artery dissection.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Aged
  • Fibrinolytic Agents / administration & dosage*
  • Humans
  • Infusions, Intravenous
  • Lateral Medullary Syndrome / diagnostic imaging
  • Lateral Medullary Syndrome / drug therapy*
  • Lateral Medullary Syndrome / physiopathology
  • Male
  • Recombinant Proteins / administration & dosage
  • Thrombolytic Therapy*
  • Tissue Plasminogen Activator / administration & dosage*
  • Treatment Outcome

Substances

  • Fibrinolytic Agents
  • Recombinant Proteins
  • Tissue Plasminogen Activator